Danita Erickson filed a retaliation lawsuit against the drugmaker in July 2018, claiming she was pressured to ensure a multiple sclerosis drug, Zinbryta, was prescribed by a hematologist to a patient with aplastic anemia, which was not an FDA-approved use.
Ms. Erickson didn’t want to pursue off-label marketing because Zinbryta had a black box warning on the product labeling, which is reserved for drugs with the most severe and potentially life-threatening side effects, the lawsuit noted.
Zinbryta was withdrawn from the U.S. market in March 2018, just before Ms. Erickson was fired, due to several reports of brain inflammation.
She filed a formal ethics complaint with the company at the end of 2017 and was fired in April 2018, after she suffered months of retaliation for filing the complaint, according to STAT.
The jury awarded her $390,500 in past economic damages, more than $2.1 million in future economic damages, $1.69 million in non-economic damages and $1.69 million in punitive damages.
Read the full article here.
More articles on pharmacy:
Amgen exits neuroscience research, cuts 180 US jobs
Walgreens’ exit from health clinic business should serve as a warning to rivals
Top 10 pharmacy stories in October
